NCT06824727

Completed

Collection of Peripheral Blood From Patients With Hematologi...

Case Comprehensive Cancer Center Source

Compare

Other study identifiers

Sponsor study identifier

CASE2424

Secondary identifiers

2R44HL145948-02

NIH

Study Type

observational

Actual enrollment (reported)

40

Locations

1 country

Sites

1

Timeline

Study Start

January 6, 2025

Actual (reported)

Primary Completion

August 21, 2025

Actual (reported)

Study Completion

August 21, 2025

Actual (reported)

Brief Summary

The purpose of the research project is to collect one blood sample from participants who are affected by very low platelets as a result of their condition or their treatment.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 40 participants
Study completion date: August 21, 2025
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 6, 2025
Actual (reported)
First Submitted
February 12, 2025
Actual (reported)
First Posted
February 13, 2025
Actual (reported)
Primary Completion
August 21, 2025
Actual (reported)
Study Completion
August 21, 2025
Actual (reported)

Last Updated: September 5, 2025
Status Verified: September 2025
Last Update Submitted: September 4, 2025

Conditions

Thrombocytopenia

Keywords

Stem Cell Transplant

Outcome Measures

Primary Outcomes (1)

Sample collection of peripheral blood from patients experiencing thrombocytopenia
Baseline

Study Arms (1)

Sample Collection

Other: Baseline cell blood counts

Interventions

Baseline cell blood countsOther

Obtain one peripheral blood sample from participants who have severe thrombocytopenia defined as 30,000 platelets/mcl or less

Sample Collection

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 88 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Samples will be collected from participants from the bone marrow transplant inpatient service and outpatient clinics.

You may qualify if:

Adults 18 years or older

Sponsors & Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
NIHcollaborator
Case Comprehensive Cancer Center
Otherlead

Study Sites (1)

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

Cleveland, Ohio, 44195, United States

MeSH Terms

Conditions

Thrombocytopenia

Condition Hierarchy (Ancestors)

Blood Platelet DisordersHematologic DiseasesHemic and Lymphatic DiseasesCytopenia

Study Officials

Paolo Caimi, MD
Case Comprehensive Cancer Center, Cleveland Clinic Taussig Cancer Institute
PRINCIPAL INVESTIGATOR

Enrollment

40 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 12, 2025

First Posted

February 13, 2025

Study Start

January 6, 2025

Actual (reported)

NCT06913374

The Study of Different Cycles of High-dose Dexamethasone in the Treatment of ITP

Phase 2/3Not Yet Recruiting

NCT06979765

Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients

Not ApplicableRecruiting

NCT01000051

Eltrombopag for Post Transplant Thrombocytopenia

Phase 2Completed

NCT05958511

Assessment of Risk Factors and Outcome of Thrombocytopenia in ICU Patients

Unknown

NCT01194167

Study of Eltrombopag in Platelet Refractory Thrombocytopenia

Phase 2Withdrawn

NCT06673498

Lusutrombopag Combined With Recombinant Human Thrombopoietin for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Destined to Undergo Elective Invasive Surgery

Phase 2Recruiting

Platelet counts of 30,000/mcl or less

You may not qualify if:

Chemotherapy within the last 24 hours from the planned blood sample draw for research purposes.
Use of anticoagulant agents in the last 48 hours.
Active infection (i.e. one that has received less than 48 hours of active treatment).
Adults 89 years or older

Contact the study team to confirm eligibility.

Primary Completion

August 21, 2025

Actual (reported)

Study Completion

August 21, 2025

Actual (reported)

Last Updated

September 5, 2025

Record last verified: 2025-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT06824727
Data provider: ClinicalTrials.gov
Source updated: 2025-09-05
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:30:29 UTC

Locations

US(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Sample Collection

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations